Reply to N. Hirshoren et al and D. Chakrabarti et al

Stephen Y Lai¹, Robert L Ferris¹

Affiliations

Affiliation

¹ Stephen Y. Lai, MD, PhD, Departments of Head and Neck Surgery, Molecular and Cellular Oncology, and Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX and Robert L. Ferris, MD, PhD, Departments of Otolaryngology, Immunology, and Radiation Oncology, UPMC Hillman Cancer Center, Pittsburgh, PA.

PMID: 33705206
DOI: 10.1200/JCO.21.00027

Comment

Reply to N. Hirshoren et al and D. Chakrabarti et al

Stephen Y Lai et al. J Clin Oncol. 2021.

. 2021 May 10;39(14):1600-1601.

doi: 10.1200/JCO.21.00027. Epub 2021 Mar 11.

Authors

Stephen Y Lai¹, Robert L Ferris¹

Affiliation

¹ Stephen Y. Lai, MD, PhD, Departments of Head and Neck Surgery, Molecular and Cellular Oncology, and Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX and Robert L. Ferris, MD, PhD, Departments of Otolaryngology, Immunology, and Radiation Oncology, UPMC Hillman Cancer Center, Pittsburgh, PA.

PMID: 33705206
DOI: 10.1200/JCO.21.00027

No abstract available

PubMed Disclaimer

Conflict of interest statement

Stephen Y. LaiConsulting or Advisory Role: Cardinal Health Robert L. FerrisStock and Other Ownership Interests: NovasentaConsulting or Advisory Role: Merck, Pfizer, EMD Serono, Numab, Macrogenics, Aduro Biotech, Novasenta, Sanofi, Zymeworks, Bristol-Myers SquibbResearch Funding: Bristol-Myers Squibb, AstraZeneca/MedImmune, Merck, Tesaro, NovasentaNo other potential conflicts of interest were reported.

Comment on

Equivalence Randomized Trial to Compare Treatment on the Basis of Sentinel Node Biopsy Versus Neck Node Dissection in Operable T1-T2N0 Oral and Oropharyngeal Cancer.
Garrel R, Poissonnet G, Moyà Plana A, Fakhry N, Dolivet G, Lallemant B, Sarini J, Vergez S, Guelfucci B, Choussy O, Bastit V, Richard F, Costes V, Landais P, Perriard F, Daures JP, de Verbizier D, Favier V, de Boutray M. Garrel R, et al. J Clin Oncol. 2020 Dec 1;38(34):4010-4018. doi: 10.1200/JCO.20.01661. Epub 2020 Oct 14. J Clin Oncol. 2020. PMID: 33052754 Clinical Trial.
Surgical Perspective on Sentinel Node Biopsy for Operable T1-T2N0 Oral and Oropharyngeal Cancer.
Hirshoren N, Weinberger JM. Hirshoren N, et al. J Clin Oncol. 2021 May 10;39(14):1598-1599. doi: 10.1200/JCO.20.03300. Epub 2021 Mar 11. J Clin Oncol. 2021. PMID: 33705202 No abstract available.
What Is the Acceptable Noninferiority Limit for Nodal Recurrences When Ascertaining Sentinel Lymph Node Biopsy as an Alternative to Neck Dissection for Early Oral and Oropharyngeal Cancers?
Chakrabarti D, Akhtar N, Rajan S, Qayoom S, Kumar V, Chaturvedi A, Verma M, Gupta R, Bhatt MLB, Parveen S. Chakrabarti D, et al. J Clin Oncol. 2021 May 10;39(14):1599-1600. doi: 10.1200/JCO.20.03439. Epub 2021 Mar 11. J Clin Oncol. 2021. PMID: 33705207 No abstract available.

Publication types

Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Other Literature Sources
- scite Smart Citations

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Reply to N. Hirshoren et al and D. Chakrabarti et al

Affiliation

Reply to N. Hirshoren et al and D. Chakrabarti et al

Authors

Affiliation

Conflict of interest statement

Comment on

Publication types

LinkOut - more resources

Full Text Sources

Other Literature Sources